Search
Acitretin
go.drugbank.com/drugs/DB00459ApprovedInvestigationalAn oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
Synonyms: (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acidIdecabtagene vicleucel
go.drugbank.com/drugs/DB16665ApprovedInvestigational[L32858] Idecabtagene vicleucel was approved by the FDA on March 26, 2021 [L32863] and by the EMA on August 18, 2021.[L51003] … [A232563] Multiple myeloma is typically treated with an immunomodulatory agent like [lenalidomide],[A232593] a proteasome inhibitor like [bortezomib], or an anti-CD38 monoclonal antibody like [isatuximab
Lumateperone
go.drugbank.com/drugs/DB06077ApprovedInvestigationalSchizophrenia is a complex mental illness and impacts approximately 1% of the population. … [A189093] Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity.
Bromfenac
go.drugbank.com/drugs/DB00963ApprovedWithdrawnNon-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] … Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes.
Palopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigational[L51134] PTH(1-34) contains the N-terminal part of the endogenous PTH molecule. … [L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA.
Synonyms: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34, Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-L-seryl-L-valyl-L-seryl-L-α-glutamyl-L-isoleSeladelpar
go.drugbank.com/drugs/DB12390ApprovedInvestigational[L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism
Ceftobiprole
go.drugbank.com/drugs/DB04918ApprovedWithdrawnThe EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European … [L50467] It received its first approval in Canada in October 2017 for use in certain patients with bacterial pneumonia,[L50472] and was subsequently approved in the United States with additional indications
Boceprevir
go.drugbank.com/drugs/DB08873ApprovedWithdrawnIn a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) do not reccomend Boceprevir in combination … Approved in May 2011 by the FDA, Victrelis is indicated for the treatment of HCV genotype 1 in combination with [DB00811], [DB00008], and [DB00022] [FDA Label].
Warfarin
go.drugbank.com/drugs/DB00682ApprovedInvestigationalWarfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. … Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America.
Categories: Compounds used in a research, industrial, or household settingSulfur hexafluoride
go.drugbank.com/drugs/DB11104ApprovedInvestigationalin adult patients with suboptimal echocardiograms •in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients … Sulfur hexafluoride is an ultrasound contrast agent indicated for use •in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border